Sector News

Merck KGaA appoints pharma head Oschmann as deputy CEO

September 18, 2014
Life sciences
(Reuters) – German drugs and chemicals maker Merck KGaA appointed the head of its pharma business, Stefan Oschmann, as deputy chief executive, it said on Thursday.
 
Oschmann, 57, will share strategic management functions and representation of the company with CEO Karl-Ludwig Kley as of Jan. 1, 2015, it said.
 
The promotion puts Oschmann in the frame to possibly succeed Kley, whose contract runs until September 2016.
 
Belen Garijo, 54, will take over leadership of the entire pharma business, according to the statement. Garijo is already CEO of Merck’s biopharmaceutical division, Merck Serono, to which she will add consumer health, allergy treatments and biosimilars.
 
(Reporting by Georgina Prodhan; Editing by Ludwig Burger)

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach